Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
October 19, 2023 17:37 ET
|
Tourmaline Bio, Inc.
Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases ...
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
October 17, 2023 17:47 ET
|
Talaris Therapeutics, Inc.
Combined Company to Trade on Nasdaq Under Ticker “TRML”Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq:...
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
October 06, 2023 17:09 ET
|
Talaris Therapeutics, Inc.
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE)...
Tourmaline Bio Appoints Gerhard Hagn as SVP, Head of Commercial and Business Development
September 20, 2023 08:00 ET
|
Tourmaline Bio, Inc.
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of...
Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED)
August 28, 2023 07:30 ET
|
Tourmaline Bio, Inc.
NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of...
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
June 22, 2023 07:30 ET
|
Talaris Therapeutics, Inc.
Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic...
Talaris Therapeutics Announces Leadership Transition
May 26, 2023 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and...
Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan
February 16, 2023 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based...
Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update
November 10, 2022 07:00 ET
|
Talaris Therapeutics, Inc.
Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual...